Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 antibody positive, in 2020. It has also been designated as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback